-
Screening mammography performance according to breast density: a comparison between radiologists versus standalone intelligence detection Breast Cancer Res. (IF 7.4) Pub Date : 2024-04-22 Mi-ri Kwon, Yoosoo Chang, Soo-Youn Ham, Yoosun Cho, Eun Young Kim, Jeonggyu Kang, Eun Kyung Park, Ki Hwan Kim, Minjeong Kim, Tae Soo Kim, Hyeonsoo Lee, Ria Kwon, Ga-Young Lim, Hye Rin Choi, JunHyeok Choi, Shin Ho Kook, Seungho Ryu
Artificial intelligence (AI) algorithms for the independent assessment of screening mammograms have not been well established in a large screening cohort of Asian women. We compared the performance of screening digital mammography considering breast density, between radiologists and AI standalone detection among Korean women. We retrospectively included 89,855 Korean women who underwent their initial
-
Clustering of HR + /HER2− breast cancer in an Asian cohort is driven by immune phenotypes Breast Cancer Res. (IF 7.4) Pub Date : 2024-04-22 Jia-Wern Pan, Mohana Ragu, Wei-Qin Chan, Siti Norhidayu Hasan, Tania Islam, Li-Ying Teoh, Suniza Jamaris, Mee-Hoong See, Cheng-Har Yip, Pathmanathan Rajadurai, Lai-Meng Looi, Nur Aishah Mohd Taib, Oscar M. Rueda, Carlos Caldas, Suet-Feung Chin, Joanna Lim, Soo-Hwang Teo
Breast cancer exhibits significant heterogeneity, manifesting in various subtypes that are critical in guiding treatment decisions. This study aimed to investigate the existence of distinct subtypes of breast cancer within the Asian population, by analysing the transcriptomic profiles of 934 breast cancer patients from a Malaysian cohort. Our findings reveal that the HR + /HER2− breast cancer samples
-
Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1–3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study Breast Cancer Res. (IF 7.4) Pub Date : 2024-04-17 Soong June Bae, Jung Whan Chun, Sae Byul Lee, Jai Min Ryu, Seok Jin Nam, Joon Jeong, Hyung Seok Park, Sung Gwe Ahn
This study investigated the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant systemic therapy (NAST) in patients with initially high nodal burden. In the multicenter retrospective cohort, 388 individuals with cN1–3 breast cancer who underwent NAST and had SLNB followed by completion axillary lymph node dissection were included. In an external validation cohort, 267 patients with HER2+ or
-
Meeting Abstracts from the British Society of Breast Radiology annual scientific meeting 2023 Breast Cancer Res. (IF 7.4) Pub Date : 2024-04-17
Proffered Papers Monday 6 November 2023 1:10 PM–2:00 PM Abstracts listed in presenting order Dr Jean Seely1, Prof Mohamed Abdolell2,3, Dr Jennifer Payne2,3, Dr Sian Iles2,3, Dr Georgia Spear4, Dr Nisha Sharma 5, Dr Laurie R. Margolies6, Dr Sylvia Heywang-Köbrunner7, Dr Toni Vomweg8 1The Ottawa Hospital, Ottawa, Canada; 2Nova Scotia Health Authority, Canada; 3Dalhousie University, Halifax, Canada; 4NorthShore
-
Selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates Breast Cancer Res. (IF 7.4) Pub Date : 2024-04-12 Soong June Bae, Yoonwon Kook, Ji Soo Jang, Seung Ho Baek, Sohyun Moon, Jung Hyun Kim, Seung Eun Lee, Min Ji Kim, Sung Gwe Ahn, Joon Jeong
Sentinel lymph node biopsy (SLNB) is recommended for patients with ductal carcinoma in situ (DCIS) undergoing mastectomy, given the concerns regarding upstaging and technical difficulties of post-mastectomy SLNB. However, this may lead to potential overtreatment, considering favorable prognosis and de-escalation trends in DCIS. Data regarding upstaging and axillary lymph node metastasis among these
-
Metabolomics assisted by transcriptomics analysis to reveal metabolic characteristics and potential biomarkers associated with treatment response of neoadjuvant therapy with TCbHP regimen in HER2 + breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-04-12 Ningning Zhang, Yuxin Huang, Guanwen Wang, Yimei Xiang, Zhouhong Jing, Junjie Zeng, Feng Yu, Xianjun Pan, Wenqi Zhou, Xiaohua Zeng
This study aimed to explore potential indicators associated with the neoadjuvant efficacy of TCbHP regimen (taxane, carboplatin, trastuzumab, and pertuzumab) in HER2 + breast cancer (BrCa) patients. A total of 120 plasma samples from 40 patients with HER2 + BrCa were prospectively collected at three treatment times of neoadjuvant therapy (NAT) with TCbHP regimen. Serum metabolites were analyzed based
-
Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-PD-1 efficacy in complementary TNBC models Breast Cancer Res. (IF 7.4) Pub Date : 2024-04-11 Robbe Salembier, Caro De Haes, Julie Bellemans, Kristel Demeyere, Wim Van Den Broeck, Niek N. Sanders, Steven Van Laere, Traci R. Lyons, Evelyne Meyer, Jonas Steenbrugge
Chitinase-like proteins (CLPs) play a key role in immunosuppression under inflammatory conditions such as cancer. CLPs are enzymatically inactive and become neutralized upon binding of their natural ligand chitin, potentially reducing CLP-driven immunosuppression. We investigated the efficacy of chitin treatment in the context of triple-negative breast cancer (TNBC) using complementary mouse models
-
Serum protein profiling reveals an inflammation signature as a predictor of early breast cancer survival Breast Cancer Res. (IF 7.4) Pub Date : 2024-04-09 Peeter Karihtala, Suvi-Katri Leivonen, Ulla Puistola, Elina Urpilainen, Anniina Jääskeläinen, Sirpa Leppä, Arja Jukkola
Breast cancers exhibit considerable heterogeneity in their biology, immunology, and prognosis. Currently, no validated, serum protein-based tools are available to evaluate the prognosis of patients with early breast cancer. The study population consisted of 521 early-stage breast cancer patients with a median follow-up of 8.9 years. Additionally, 61 patients with breast fibroadenoma or atypical ductal
-
U2AF2-SNORA68 promotes triple-negative breast cancer stemness through the translocation of RPL23 from nucleoplasm to nucleolus and c-Myc expression Breast Cancer Res. (IF 7.4) Pub Date : 2024-04-09 Wenrong Zhang, Xinyue Song, Zining Jin, Yiqi Zhang, Shan Li, Feng Jin, Ang Zheng
Small nucleolar RNAs (snoRNAs) play key roles in ribosome biosynthesis. However, the mechanism by which snoRNAs regulate cancer stemness remains to be fully elucidated. SNORA68 expression was evaluated in breast cancer tissues by in situ hybridization and qRT‒PCR. Proliferation, migration, apoptosis and stemness analyses were used to determine the role of SNORA68 in carcinogenesis and stemness maintenance
-
Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients Breast Cancer Res. (IF 7.4) Pub Date : 2024-04-08 Kirsten M. Woolpert, Julie A. Schmidt, Thomas P. Ahern, Cathrine F. Hjorth, Dóra K. Farkas, Bent Ejlertsen, Lindsay J. Collin, Timothy L. Lash, Deirdre P. Cronin-Fenton
Patients with hormone receptor positive breast cancer are recommended at least five years of adjuvant endocrine therapy, but adherence to this treatment is often suboptimal. We investigated longitudinal trends in adjuvant endocrine therapy (AET) adherence among premenopausal breast cancer patients and identified clinical characteristics, including baseline comorbidities and non-cancer chronic medication
-
Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications Breast Cancer Res. (IF 7.4) Pub Date : 2024-04-02 Muhammad Hasan Bashari, Fengjuan Fan, Sonia Vallet, Martin Sattler, Melissa Arn, Claudia Luckner-Minden, Henning Schulze-Bergkamen, Inka Zörnig, Frederik Marme, Andreas Schneeweiss, Michael H. Cardone, Joseph T. Opferman, Dirk Jäger, Klaus Podar
Correction: Breast Cancer Research (2016) 18:26 https://doi.org/10.1186/s13058-016-0686-4 Following the publication of the original article [1], the author reported that PARP blots of JIMT-1 and JIMT-1-BR3 cells in Fig. 7C of the original publication were mistakenly duplicated. Error image The correct figure below depicts the correct PARP blot for JIMT-1 cells. Correct image The error does not affect
-
Establishing conditions for the generation and maintenance of estrogen receptor-positive organoid models of breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-29 Michael U J Oliphant, Dipikaa Akshinthala, Senthil K. Muthuswamy
Patient-derived organoid models of estrogen receptor-positive (ER+) breast cancer would provide a much-needed tool to understand drug resistance and disease progression better. However, the establishment and long-term maintenance of ER expression, function, and response in vitro remains a significant challenge. Here, we report the development of an ER+ breast tumor organoid medium (BTOM-ER) that conserves
-
Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-29 Gerald Wallace, Ronak Kundalia, Ethan Vallebuona, Biwei Cao, Youngchul Kim, Peter Forsyth, Aixa Soyano, Inna Smalley, Yolanda Pina
Breast cancer-related leptomeningeal disease (BC-LMD) is a dire diagnosis for 5–8% of patients with breast cancer (BC). We conducted a retrospective review of BC-LMD patients diagnosed at Moffitt Cancer Center from 2011 to 2020, to determine the changing incidence of BC-LMD, factors which are associated with the progression of BC CNS metastasis to BC-LMD, and factors which are associated with OS for
-
Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-29 Feng Chi, Jason I. Griffiths, Aritro Nath, Andrea H. Bild
Fibroblast growth factors (FGFs) control various cellular functions through fibroblast growth factor receptor (FGFR) activation, including proliferation, differentiation, migration, and survival. FGFR amplification in ER + breast cancer patients correlate with poor prognosis, and FGFR inhibitors are currently being tested in clinical trials. By comparing three-dimensional spheroid growth of ER + breast
-
Exploring the dynamic interplay between exosomes and the immune tumor microenvironment: implications for breast cancer progression and therapeutic strategies Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-29 Sahar Safaei, Manouchehr Fadaee, Omid Rahbar Farzam, Amirhossein Yari, Elham Poursaei, Cynthia Aslan, Sahar Samemaleki, Dariush Shanehbandi, Behzad Baradaran, Tohid Kazemi
Breast cancer continues to pose a substantial worldwide health concern, demanding a thorough comprehension of the complex interaction between cancerous cells and the immune system. Recent studies have shown the significant function of exosomes in facilitating intercellular communication and their participation in the advancement of cancer. Tumor-derived exosomes have been identified as significant
-
Correction: The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-26 Jing Qian, Yanxia Ma, William M. Tahaney, Cassandra L. Moyer, Amanda Lanier, Jamal Hill, Darian Coleman, Negar Koupaei, Susan G. Hilsenbeck, Michelle I. Savage, Brent D. G. Page, Abhijit Mazumdar, Powel H. Brown
Qian et al. Breast Cancer Research (2024) 26:23 https://doi.org/10.1186/s13058-024-01778-w The original article has incomplete funding information with regard to author Negar Koupaei. The complete funding note is as follows: Funding This work was funded by a Susan G Komen Promise Grant (KG081694 P.H.B.), a Komen SAB Grant (9SAB12-00006, P.H.B.), and a CCSG Grant (P30 CA016672, P.H.B.). This work was
-
Temporal changes in mammographic breast density and breast cancer risk among women with benign breast disease Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-26 Maeve Mullooly, Shaoqi Fan, Ruth M. Pfeiffer, Erin Aiello Bowles, Máire A. Duggan, Roni T. Falk, Kathryn Richert-Boe, Andrew G. Glass, Teresa M. Kimes, Jonine D. Figueroa, Thomas E. Rohan, Mustapha Abubakar, Gretchen L. Gierach
Benign breast disease (BBD) and high mammographic breast density (MBD) are prevalent and independent risk factors for invasive breast cancer. It has been suggested that temporal changes in MBD may impact future invasive breast cancer risk, but this has not been studied among women with BBD. We undertook a nested case–control study within a cohort of 15,395 women with BBD in Kaiser Permanente Northwest
-
Expression- and splicing-based multi-tissue transcriptome-wide association studies identified multiple genes for breast cancer by estrogen-receptor status Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-21 Julian C. McClellan, James L. Li, Guimin Gao, Dezheng Huo
Although several transcriptome-wide association studies (TWASs) have been performed to identify genes associated with overall breast cancer (BC) risk, only a few TWAS have explored the differences in estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) breast cancer. Additionally, these studies were based on gene expression prediction models trained primarily in breast tissue, and
-
BIRC5 expression by race, age and clinical factors in breast cancer patients Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-21 Alina M. Hamilton, Andrea Walens, Sarah C. Van Alsten, Linnea T. Olsson, Joseph Nsonwu-Farley, Xiaohua Gao, Erin L. Kirk, Charles M. Perou, Lisa A. Carey, Melissa A. Troester, Yara Abdou
Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5 has not been well studied among racially diverse populations where aggressive breast cancers are prevalent. We studied BIRC5 expression in association with clinical and demographic variables and as a predictor of recurrence in 2174 participants in the
-
Factors associated with engraftment success of patient-derived xenografts of breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-21 Jongwon Lee, GunHee Lee, Hye Seon Park, Byung-Kwan Jeong, Gyungyub Gong, Jae Ho Jeong, Hee Jin Lee
Patient-derived xenograft (PDX) models serve as a valuable tool for the preclinical evaluation of novel therapies. They closely replicate the genetic, phenotypic, and histopathological characteristics of primary breast tumors. Despite their promise, the rate of successful PDX engraftment is various in the literature. This study aimed to identify the key factors associated with successful PDX engraftment
-
TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9 Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-19 Ran Hu, Yu Cao, Yuanyuan Wang, Tingting Zhao, Kaibo Yang, Mingwei Fan, Mengyao Guan, Yuekang Hou, Jiao Ying, Xiaowen Ma, Ning Deng, Xun Sun, Yong Zhang, Xiupeng Zhang
Breast cancer stem cell (CSC) expansion results in tumor progression and chemoresistance; however, the modulation of CSC pluripotency remains unexplored. Transmembrane protein 120B (TMEM120B) is a newly discovered protein expressed in human tissues, especially in malignant tissues; however, its role in CSC expansion has not been studied. This study aimed to determine the role of TMEM120B in transcriptional
-
Breast cancer survivors suffering from lymphedema: What really do affect to corporeality/body image? A qualitative study Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-14 Laura González-Fernández, Carlos Romero-Morales, Beatriz Martínez-Pascual, Angela Río-González, Ester Cerezo-Téllez, Inmaculada López-Martín
Breast cancer-related lymphedema is currently one of the most serious complications that most affect the quality of life of women undergoing breast cancer. The aim of this study was to explore in-depth the experience of women who suffer from lymphoedema after breast cancer and how does this condition affect corporeality, with no judgements. For this purpose, a qualitative methodology was followed.
-
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-13 Rebecca A. Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B. Schwab, Emily I. Pittman, Minya Pu, Elizabeth Weihe, Emanuela M. Ghia, Laura Z. Rassenti, Alfredo Molinolo, Betty Cabrera, James B. Breitmeyer, George F. Widhopf II, Karen Messer, Catriona Jamieson, Thomas J. Kipps, Barbara A. Parker
Correction to: Shatsky et al. Breast Cancer Research (2024) 26:32https://doi.org/10.1186/s13058-024-01782-0 The original article contained three typesetting errors. “Her2-negative” in the title should have been written as “HER2-negative”. Hence, the title should read: A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast
-
Breast composition during and after puberty: the Chilean Growth and Obesity Cohort Study Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-12 Ana Pereira, María Luisa Garmendia, Valeria Leiva, Camila Corvalán, Karin B. Michels, John Shepherd
Breast density (BD) is a strong risk factor for breast cancer. Little is known about how BD develops during puberty. Understanding BD trajectories during puberty and its determinants could be crucial for promoting preventive actions against breast cancer (BC) at early ages. The objective of this research is to characterize % fibroglandular volume (%FGV), absolute fibroglandular volume (AFGV), and breast
-
UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5 Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-11 Juan Li, Yu Liang, Shijie Zhou, Jie Chen, Chihua Wu
Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) is a deubiquitinating enzyme that regulates ERα expression in triple-negative cancer (TNBC). This study aimed to explore the deubiquitination substrates of UCHL1 related to endocrine therapeutic responses and the mechanisms of UCHL1 dysregulation in TNBC. Bioinformatics analysis was conducted using online open databases. TNBC representative MDA-MB-468
-
Cell morphology best predicts tumorigenicity and metastasis in vivo across multiple TNBC cell lines of different metastatic potential Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-11 Sydney J. Conner, Justinne R. Guarin, Thanh T. Le, Jackson P. Fatherree, Charlotte Kelley, Samantha L. Payne, Savannah R. Parker, Hanan Bloomer, Crystal Zhang, Kenneth Salhany, Rachel A. McGinn, Emily Henrich, Anna Yui, Deepti Srinivasan, Hannah Borges, Madeleine J. Oudin
Metastasis is the leading cause of death in breast cancer patients. For metastasis to occur, tumor cells must invade locally, intravasate, and colonize distant tissues and organs, all steps that require tumor cell migration. The majority of studies on invasion and metastasis rely on human breast cancer cell lines. While it is known that these cells have different properties and abilities for growth
-
The role of surgical tissue injury and intraoperative sympathetic activation in postoperative immunosuppression after breast-conserving surgery versus mastectomy: a prospective observational study Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-11 Lotte MC Jacobs, Leonie S Helder, Kim I Albers, Josephine Kranendonk, Christiaan Keijzer, Leo AB Joosten, Luc JA Strobbe, Michiel C Warlé
Breast cancer is the second most common cause of death from cancer in women worldwide. Counterintuitively, large population-based retrospective trials report better survival after breast-conserving surgery (BCS) compared to mastectomy, corrected for tumour- and patient variables. More extensive surgical tissue injury and activation of the sympathetic nervous system by nociceptive stimuli are associated
-
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected? Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-11 Ximena Baez-Navarro, Nadine S. van den Ende, Anh H. Nguyen, Renata Sinke, Pieter Westenend, Johannes Bastiaan van Brakel, Claudia Stobbe, Johan Westerga, Carolien H. M. van Deurzen
Most patients with triple-negative breast cancer (TNBC) are not candidates for targeted therapy, leaving chemotherapy as the primary treatment option. Recently, immunotherapy has demonstrated promising results in TNBC, due to its immunogenicity. In addition, a novel antibody–drug conjugate, namely, trastuzumab-deruxtecan, has shown effectiveness in TNBC patients with low-HER2 expression (HER2-low)
-
Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-08 Lingzhou Zhao, Yan Xing, Changcun Liu, Shaofei Ma, Wenhua Huang, Zhen Cheng, Jinhua Zhao
99mTc radiolabeled nanobody NM-02 (99mTc-NM-02) is a novel single photon emission computed tomography (SPECT) probe with a high affinity and specificity for human epidermal growth factor receptor 2 (HER2). In this study, a clinical imaging trial was conducted to investigate the relationship between 99mTc-NM-02 uptake and HER2 expression in patients with breast cancer. Thirty patients with pathologically
-
How does weight gain since the age of 18 years affect breast cancer risk in later life? A meta-analysis Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-07 Yunan Han, Ebunoluwa E. Otegbeye, Carrie Stoll, Angela Hardi, Graham A. Colditz, Adetunji T. Toriola
Early life factors are important risk factors for breast cancer. The association between weight gain after age 18 and breast cancer risk is inconsistent across previous epidemiologic studies. To evaluate this association, we conducted a meta-analysis according to PRISMA guidelines and the established inclusion criteria. We performed a comprehensive literature search using Medline (Ovid), Embase, Scopus
-
Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-07 Miguel Castresana-Aguirre, Annelie Johansson, Alexios Matikas, Theodoros Foukakis, Linda S. Lindström, Nicholas P. Tobin
The clinical utility of gene signatures in older breast cancer patients remains unclear. We aimed to determine signature prognostic capacity in this patient subgroup. Research versions of the genomic grade index (GGI), 70-gene, recurrence score (RS), cell cycle score (CCS), PAM50 risk-of-recurrence proliferation (ROR-P), and PAM50 signatures were applied to 39 breast cancer datasets (N = 9583). After
-
The FBXW7-binding sites on FAM83D are potential targets for cancer therapy Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-07 Xiaoyu Jiang, Yuli Wang, Lulu Guo, Yige Wang, Tianshu Miao, Lijuan Ma, Qin Wei, Xiaoyan Lin, Jian-Hua Mao, Pengju Zhang
Increasing evidence shows the oncogenic function of FAM83D in human cancer, but how FAM83D exerts its oncogenic function remains largely unclear. Here, we investigated the importance of FAM83D/FBXW7 interaction in breast cancer (BC). We systematically mapped the FBXW7-binding sites on FAM83D through a comprehensive mutational analysis together with co-immunoprecipitation assay. Mutations at the FBXW7-binding
-
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-04 Jordi Rodón, David Demanse, Hope S. Rugo, Howard A. Burris, Rafael Simó, Azeez Farooki, Melissa F. Wellons, Fabrice André, Huilin Hu, Dragica Vuina, Cornelia Quadt, Dejan Juric
Hyperglycemia is an on-target effect of PI3Kα inhibitors. Early identification and intervention of treatment-induced hyperglycemia is important for improving management of patients receiving a PI3Kα inhibitor like alpelisib. Here, we characterize incidence of grade 3/4 alpelisib-related hyperglycemia, along with time to event, management, and outcomes using a machine learning model. Data for the risk
-
Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis Breast Cancer Res. (IF 7.4) Pub Date : 2024-03-01 Stephen G. Smoots, Anna R. Schreiber, Marilyn M. Jackson, Stacey M. Bagby, Adrian T A. Dominguez, Evan D. Dus, Cameron A. Binns, Morgan MacBeth, Phaedra A. Whitty, Jennifer R. Diamond, Todd M. Pitts
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. Doxorubicin is part of standard curative therapy for TNBC, but chemotherapy resistance remains an important clinical challenge. Bocodepsin (OKI-179) is a small molecule class I histone deacetylase (HDAC) inhibitor that promotes apoptosis in TNBC preclinical models. The purpose of this study was to investigate
-
PTHrP intracrine actions divergently influence breast cancer growth through p27 and LIFR Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-26 Courtney M. Edwards, Jeremy F. Kane, Jailyn A. Smith, Déja M. Grant, Jasmine A. Johnson, Maria A. Hernandez Diaz, Lawrence A. Vecchi, Kai M. Bracey, Tolu N. Omokehinde, Joseph R. Fontana, Breelyn A. Karno, Halee T. Scott, Carolina J. Vogel, Jonathan W. Lowery, T. John Martin, Rachelle W. Johnson
The role of parathyroid hormone (PTH)-related protein (PTHrP) in breast cancer remains controversial, with reports of PTHrP inhibiting or promoting primary tumor growth in preclinical studies. Here, we provide insight into these conflicting findings by assessing the role of specific biological domains of PTHrP in tumor progression through stable expression of PTHrP (-36-139aa) or truncated forms with
-
Small molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-26 Ting Song, Hong Zhang, Qicheng Zhao, Zhiyuan Hu, Ziqian Wang, Yang Song, Zhichao Zhang
Estrogen receptor (ER) positive patients compromise about 70% of breast cancers. Tamoxifen, an antagonist of ERα66 (the classic ER), is the most effective and the standard first-line drug. However, its efficacy is limited by the development of acquired resistance. A specific inhibitor of Hsp70-Bim protein–protein interaction (PPI), S1g-2, together with an inhibitor of Hsp70-Bag3 PPI, MKT-077 and an
-
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-26 Rebecca A. Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B. Schwab, Emily I. Pittman, Minya Pu, Elizabeth Weihe, Emanuela M. Ghia, Laura Z. Rassenti, Alfredo Molinolo, Betty Cabrera, James B. Breitmeyer, George F. Widhopf, Karen Messer, Catriona Jamieson, Thomas J. Kipps, Barbara A. Parker
Zilovertamab is a humanized monoclonal antibody targeting ROR1, an onco-embryonic antigen expressed by malignant cells of a variety of solid tumors, including breast cancer. A prior phase 1 study showed that zilovertamab was well tolerated and effective in inhibiting ROR1-signaling, which leads to activation of ERK1/2, NF-κB, and NRF2 target genes. This phase 1b study evaluated the safety and tolerability
-
Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-23 Minsun Jung, Seung Geun Song, Soo Ick Cho, Sangwon Shin, Taebum Lee, Wonkyung Jung, Hajin Lee, Jiyoung Park, Sanghoon Song, Gahee Park, Heon Song, Seonwook Park, Jinhee Lee, Mingu Kang, Jongchan Park, Sergio Pereira, Donggeun Yoo, Keunhyung Chung, Siraj M. Ali, So-Woon Kim
Accurate classification of breast cancer molecular subtypes is crucial in determining treatment strategies and predicting clinical outcomes. This classification largely depends on the assessment of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) status. However, variability in interpretation among pathologists pose challenges to the accuracy of
-
The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [177Lu]Lu-PSMA-I&T for triple-negative breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-20 Amelie Heesch, Alexandru Florea, Jochen Maurer, Pardes Habib, Laura S. Werth, Thomas Hansen, Elmar Stickeler, Sabri E. M. Sahnoun, Felix M. Mottaghy, Agnieszka Morgenroth
Overexpression of prostate-specific membrane antigen (PSMA) on the vasculature of triple-negative breast cancer (TNBC) presents a promising avenue for targeted endogenous radiotherapy with [177Lu]Lu-PSMA-I&T. This study aimed to assess and compare the therapeutic efficacy of a single dose with a fractionated dose of [177Lu]Lu-PSMA-I&T in an orthotopic model of TNBC. Rj:NMRI-Foxn1nu/nu mice were used
-
Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-19 Françoise Derouane, Manon Desgres, Camilla Moroni, Jérôme Ambroise, Martine Berlière, Mieke R. Van Bockstal, Christine Galant, Cédric van Marcke, Marianela Vara-Messler, Stefan J. Hutten, Jos Jonkers, Larissa Mourao, Colinda L. G. J. Scheele, Francois P. Duhoux, Cyril Corbet
Neoadjuvant chemotherapy (NAC) is the standard of care for patients with early-stage triple negative breast cancers (TNBC). However, more than half of TNBC patients do not achieve a pathological complete response (pCR) after NAC, and residual cancer burden (RCB) is associated with dismal long-term prognosis. Understanding the mechanisms underlying differential treatment outcomes is therefore critical
-
Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-15 Claire Scheffges, Jérôme Devy, Jérôme Giustiniani, Stessy Francois, Lucille Cartier, Yacine Merrouche, Arnaud Foussat, Stéphane Potteaux, Armand Bensussan, Anne Marie-Cardine
Despite major therapeutic advances, triple-negative breast cancer (TNBC) still presents a worth prognosis than hormone receptors-positive breast cancers. One major issue relies in the molecular and mutational heterogeneity of TNBC subtypes that is reinforced by the absence of reliable tumor-antigen that could serve as a specific target to further promote efficient tumor cell recognition and depletion
-
Contrast-enhanced ultrasound to predict malignant upgrading of atypical ductal hyperplasia Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-12 Jun Kang Li, Zhi Ying Jin, Yong Jie Xu, Nai Qin Fu, Ying Jiang, Shi Yu Li, Rui Lan Niu, Gang Liu, Zhi Li Wang
A malignancy might be found at surgery in cases of atypical ductal hyperplasia (ADH) diagnosed via US-guided core needle biopsy (CNB). The objective of this study was to investigate the diagnostic performance of contrast-enhanced ultrasound (CEUS) in predicting ADH diagnosed by US-guided CNB that was upgraded to malignancy after surgery. In this retrospective study, 110 CNB-diagnosed ADH lesions in
-
MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-12 Mengfan Wang, Siyao Du, Si Gao, Ruimeng Zhao, Shasha Liu, Wenhong Jiang, Can Peng, Ruimei Chai, Lina Zhang
MRI-based tumor shrinkage patterns (TSP) after neoadjuvant therapy (NAT) have been associated with pathological response. However, the understanding of TSP after early NAT remains limited. We aimed to analyze the relationship between TSP after early NAT and pathological response after therapy in different molecular subtypes. We prospectively enrolled participants with invasive ductal breast cancers
-
Are better AI algorithms for breast cancer detection also better at predicting risk? A paired case–control study Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-07 Ruggiero Santeramo, Celeste Damiani, Jiefei Wei, Giovanni Montana, Adam R. Brentnall
There is increasing evidence that artificial intelligence (AI) breast cancer risk evaluation tools using digital mammograms are highly informative for 1–6 years following a negative screening examination. We hypothesized that algorithms that have previously been shown to work well for cancer detection will also work well for risk assessment and that performance of algorithms for detection and risk
-
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-07 Caroline Rönnlund, Emmanouil G. Sifakis, Caroline Schagerholm, Qiao Yang, Emelie Karlsson, Xinsong Chen, Theodoros Foukakis, Jodi Weidler, Michael Bates, Irma Fredriksson, Stephanie Robertson, Johan Hartman
Overexpression of human epidermal growth factor receptor 2 (HER2) caused by HER2 gene amplification is a driver in breast cancer tumorigenesis. We aimed to investigate the prognostic significance of manual scoring and digital image analysis (DIA) algorithm assessment of HER2 copy numbers and HER2/CEP17 ratios, along with ERBB2 mRNA levels among early-stage HER2-positive breast cancer patients treated
-
The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-05 Jing Qian, Yanxia Ma, William M. Tahaney, Cassandra L. Moyer, Amanda Lanier, Jamal Hill, Darian Coleman, Negar Koupaei, Susan G. Hilsenbeck, Michelle I. Savage, Brent D. G. Page, Abhijit Mazumdar, Powel H. Brown
The most aggressive form of breast cancer is triple-negative breast cancer (TNBC), which lacks expression of the estrogen receptor (ER) and progesterone receptor (PR), and does not have overexpression of the human epidermal growth factor receptor 2 (HER2). Treatment options for women with TNBC tumors are limited, unlike those with ER-positive tumors that can be treated with hormone therapy, or those
-
Low-dose acetylsalicylic acid reduces local inflammation and tissue perfusion in dense breast tissue in postmenopausal women Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-05 Peter Lundberg, Annelie Abrahamsson, Johan Kihlberg, Jens Tellman, Ieva Tomkeviciene, Anette Karlsson, Maria Kristoffersen Wiberg, Marcel Warntjes, Charlotta Dabrosin
One major risk factor for breast cancer is high mammographic density. It has been estimated that dense breast tissue contributes to ~ 30% of all breast cancer. Prevention targeting dense breast tissue has the potential to improve breast cancer mortality and morbidity. Anti-estrogens, which may be associated with severe side-effects, can be used for prevention of breast cancer in women with high risk
-
Improving lesion detection in mammograms by leveraging a Cycle-GAN-based lesion remover Breast Cancer Res. (IF 7.4) Pub Date : 2024-02-01 Juhun Lee, Robert M. Nishikawa
The wide heterogeneity in the appearance of breast lesions and normal breast structures can confuse computerized detection algorithms. Our purpose was therefore to develop a Lesion Highlighter (LH) that can improve the performance of computer-aided detection algorithms for detecting breast cancer on screening mammograms. We hypothesized that a Cycle-GAN based Lesion Remover (LR) could act as an LH
-
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-31 Filipa Lynce, Laura E. Stevens, Zheqi Li, Jane E. Brock, Anushree Gulvady, Ying Huang, Faina Nakhlis, Ashka Patel, Jeremy M. Force, Tufia C. Haddad, Naoto Ueno, Vered Stearns, Antonio C. Wolff, Amy S. Clark, Jennifer R. Bellon, Edward T. Richardson, Justin M. Balko, Ian E. Krop, Eric P. Winer, Paulina Lange, E. Shelley Hwang, Tari A. King, Sara M. Tolaney, Alastair Thompson, Gaorav P. Gupta, Elizabeth
Patients with inflammatory breast cancer (IBC) have overall poor clinical outcomes, with triple-negative IBC (TN-IBC) being associated with the worst survival, warranting the investigation of novel therapies. Preclinical studies implied that ruxolitinib (RUX), a JAK1/2 inhibitor, may be an effective therapy for TN-IBC. We conducted a randomized phase II study with nested window-of-opportunity in TN-IBC
-
ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-29 Jiahui Nie, Suying Dang, Rui Zhu, Tiantian Lu, Wei Zhang
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for about 20% of all breast cancer cases and is correlated with a high relapse rate and poor prognosis. ADAMTS18 is proposed as an important functional tumor suppressor gene involved in multiple malignancies, including breast cancer. It functions as an extracellular matrix (ECM) modifier. However, it remains unclear whether
-
Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-29 Xiaorui Han, Yuan Guo, Huifen Ye, Zhihong Chen, Qingru Hu, Xinhua Wei, Zaiyi Liu, Changhong Liang
Since breast cancer patients respond diversely to immunotherapy, there is an urgent need to explore novel biomarkers to precisely predict clinical responses and enhance therapeutic efficacy. The purpose of our present research was to construct and independently validate a biomarker of tumor microenvironment (TME) phenotypes via a machine learning-based radiomics way. The interrelationship between the
-
Development and prognostic validation of a three-level NHG-like deep learning-based model for histological grading of breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-29 Abhinav Sharma, Philippe Weitz, Yinxi Wang, Bojing Liu, Johan Vallon-Christersson, Johan Hartman, Mattias Rantalainen
Histological grade is a well-known prognostic factor that is routinely assessed in breast tumours. However, manual assessment of Nottingham Histological Grade (NHG) has high inter-assessor and inter-laboratory variability, causing uncertainty in grade assignments. To address this challenge, we developed and validated a three-level NHG-like deep learning-based histological grade model (predGrade). The
-
A genome-wide association study of contralateral breast cancer in the Women’s Environmental Cancer and Radiation Epidemiology Study Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-23 Xiaohui Sun, Anne S. Reiner, Anh Phong Tran, Gordon P. Watt, Jung Hun Oh, Lene Mellemkjær, Charles F. Lynch, Julia A. Knight, Esther M. John, Kathleen E. Malone, Xiaolin Liang, Meghan Woods, Andriy Derkach, Patrick Concannon, Jonine L. Bernstein, Xiang Shu
Contralateral breast cancer (CBC) is the most common second primary cancer diagnosed in breast cancer survivors, yet the understanding of the genetic susceptibility of CBC, particularly with respect to common variants, remains incomplete. This study aimed to investigate the genetic basis of CBC to better understand this malignancy. We performed a genome-wide association analysis in the Women’s Environmental
-
Differential patterns of reproductive and lifestyle risk factors for breast cancer according to birth cohorts among women in China, Japan and Korea Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-22 Salma Nabila, Ji-Yeob Choi, Sarah Krull Abe, Md Rashedul Islam, Md Shafiur Rahman, Eiko Saito, Aesun Shin, Melissa A. Merritt, Ryoko Katagiri, Xiao-Ou Shu, Norie Sawada, Akiko Tamakoshi, Ritsu Sakata, Atsushi Hozawa, Jeongseon Kim, Chisato Nagata, Sue K. Park, Sun-Seog Kweon, Hui Cai, Shoichiro Tsugane, Takashi Kimura, Seiki Kanemura, Yumi Sugawara, Keiko Wada, Min-Ho Shin, Habibul Ahsan, Paolo Boffetta
The birth cohort effect has been suggested to influence the rate of breast cancer incidence and the trends of associated reproductive and lifestyle factors. We conducted a cohort study to determine whether a differential pattern of associations exists between certain factors and breast cancer risk based on birth cohorts. This was a cohort study using pooled data from 12 cohort studies. We analysed
-
Increased risk of contralateral breast cancer for BRCA1/2 wild-type, high-risk Korean breast cancer patients: a retrospective cohort study Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-22 Eunhye Kang, Ji-Jung Jung, Changjin Lim, Hong-Kyu Kim, Han-Byoel Lee, Wonshik Han, Hyeong-Gon Moon
This study aimed to investigate the contralateral breast cancer (CBC) recurrence rate in Korean breast cancer patients according to their BRCA1/2 germline mutation status, focusing particularly on the CBC recurrence risk in BRCA1/2 negative (BRCAx) patients. We conducted a retrospective study on 13,107 primary breast cancer patients. The patients were divided into high-risk and low-risk groups for
-
c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-18 Jieun Park, Eun Sol Chang, Ji-Yeon Kim, Chaithanya Chelakkot, Minjung Sung, Ji-Young Song, Kyungsoo Jung, Ji Hye Lee, Jun Young Choi, Na Young Kim, Hyegyeong Lee, Mi-Ran Kang, Mi Jeong Kwon, Young Kee Shin, Yeon Hee Park, Yoon-La Choi
Endocrine therapy resistance in hormone receptor-positive/HER2-negative (HR+/HER2−) breast cancer (BC) is a significant clinical challenge that poses several unmet needs in the management of the disease. This study aimed to investigate the prognostic value of c-MET-positive circulating tumor cells (cMET+ CTCs), ESR1/PIK3CA mutations, and cell-free DNA (cfDNA) concentrations in patients with hormone
-
Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-18 Timothy B. Fisher, Geetanjali Saini, T. S. Rekha, Jayashree Krishnamurthy, Shristi Bhattarai, Grace Callagy, Mark Webber, Emiel A. M. Janssen, Jun Kong, Ritu Aneja
Pathological complete response (pCR) is associated with favorable prognosis in patients with triple-negative breast cancer (TNBC). However, only 30–40% of TNBC patients treated with neoadjuvant chemotherapy (NAC) show pCR, while the remaining 60–70% show residual disease (RD). The role of the tumor microenvironment in NAC response in patients with TNBC remains unclear. In this study, we developed a
-
Evidence of steady-state fibroblast subtypes in the normal human breast as cells-of-origin for perturbed-state fibroblasts in breast cancer Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-16 Mikkel Morsing Bagger, Jonas Sjölund, Jiyoung Kim, Katharina Theresa Kohler, René Villadsen, Abbas Jafari, Moustapha Kassem, Kristian Pietras, Lone Rønnov-Jessen, Ole William Petersen
Human breast cancer most frequently originates within a well-defined anatomical structure referred to as the terminal duct lobular unit (TDLU). This structure is endowed with its very own lobular fibroblasts representing one out of two steady-state fibroblast subtypes—the other being interlobular fibroblasts. While cancer-associated fibroblasts (CAFs) are increasingly appreciated as covering a spectrum
-
PFKP deubiquitination and stabilization by USP5 activate aerobic glycolysis to promote triple-negative breast cancer progression Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-12 Zi-Mei Peng, Xiao-Jian Han, Tao Wang, Jian-Jun Li, Chun-Xi Yang, Fang-Fang Tou, Zhen Zhang
Triple-negative breast cancer (TNBC) remains the most challenging subtype of breast cancer and lacks definite treatment targets. Aerobic glycolysis is a hallmark of metabolic reprogramming that contributes to cancer progression. PFKP is a rate-limiting enzyme involved in aerobic glycolysis, which is overexpressed in various types of cancers. However, the underlying mechanisms and roles of the posttranslational
-
Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial Breast Cancer Res. (IF 7.4) Pub Date : 2024-01-11 Nianhua Ding, Jian Pang, Xuan Liu, Xiongbin He, Wei Zhou, Haiqing Xie, Jianqi Feng, Guo Wang, Jie Tang, Jing Cao, Liying He, Yingjian He, Shouman Wang, Zhi Xiao
This study aimed to evaluate the prognostic role of the baseline neutrophil/lymphocyte ratio (NLR) in HER2-positive metastatic breast cancer (MBC) patients treated with trastuzumab/pertuzumab. Data from 780 patients from the CLEOPATRA trial and 248 local patients were collected. Patients were divided into the low and high NLR subgroups by the NLR cutoff value. Propensity score matching (PSM) and inverse